CD4 and neoplasm: Interestingly, anti-PD-L1 treatments did not significantly change the proportions of intratumoral CD4+ and CD8+ T cells but significantly decreased the percentages of tumor-infiltrating PD-L1+ myeloid and lymphoid cells, compared to the control group (Supplementary Figure S1b, c, and S2).